drugset / Trial / NCT03703908
A Study of CCX140-B in Subjects With Primary FSGS and Nephrotic Syndrome
NaSequentialOpen-labelTreatment
Summary
An Open Label, Intra-Subject Dose Escalation Study of CCX140 B in Subjects with Primary FSGS and Nephrotic Syndrome
Timeline
- Start
- 2018-10-01
- Primary completion
- 2020-06-24
- Completion
- 2020-06-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CCX140-B | Small molecule | 15 mg | Oral |